

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**Gold River Productions, Inc.**

A Colorado Corporation

4 Office Park Drive, Pod 3, Suite L
Palm Coast, FL 32137

(321) 266-6895<https://www.grpsinc.com/>

2000 – SIC Code

Quarterly Report**For the Period Ending:** March 31, 2022

(the “Reporting Period”)

As of March 31, 2022, the number of shares outstanding of our Common Stock was: 1,238,901,842.As of December 31, 2021, the number of shares outstanding of our Common Stock was: 1,238,901,842.As of December 31, 2021, the number of shares outstanding of our Common Stock was: 1,238,901,842.

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company’s shell status has changed since the previous reporting period:

Yes: No: Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:Yes: No: **1) Name of the issuer and its predecessors (if any)**

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer’s current standing in its state of incorporation (e.g. active, default, inactive):

¹ This is not legal advice, and OTC Markets Group makes no assurance that compliance with our disclosure requirements will satisfy any legal requirements.² Publication of information pursuant to these Guidelines does not guarantee or ensure that the Company will be designated as having “current information” or eligible for public quotations pursuant to Rule 15c2-11 or any other applicable regulation.³ OTC Markets Group may require companies with securities designated as Caveat Emptor to make additional disclosures in order to qualify for the Pink Current Information tier.

Original Incorporation in Delaware on September 18, 2006, as Omega Environmental, Inc.
 Formed on September 16, 2006 as Omega Environmental, Inc. until 9-06
 9-06 O.N.E. World Distributing, Inc. until 12-06
 12-06 it became Polythene Metro, Inc. until 2-07
 07/25/2018 it became Gold River Production Services, Inc., redomiciling from Delaware and converting to a Colorado corporation
 08/28/2018 name changed to XYZ Hemp Inc.
 09/30/2019 name changed back to Gold River Production Services, Inc. – Active.

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below: None

The address(es) of the issuer's principal executive office:

4 Office Park Drive, Pod 3, Suite L
 Palm Coast, FL 32137

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: [X]

2) Security Information

Trading symbol:	<u>GRPS</u>
Exact title and class of securities outstanding:	<u>Common</u>
CUSIP:	<u>380708206</u>
Par or stated value:	<u>\$0.000001</u>

Total shares authorized:	<u>1,300,000,000</u>	as of date: <u>March 31, 2022</u>
Total shares outstanding:	<u>1,238,901,842</u>	as of date: <u>March 31, 2022</u>
Number of shares in the Public Float ² :	<u>1,054,891,749</u>	as of date: <u>March 31, 2022</u>
Total number of shareholders of record:	<u>3,828</u>	as of date: <u>March 31, 2022</u>

All additional classes of publicly traded securities (if any):

Transfer Agent

Name: Mountain Share Transfer, LLC.
 Phone: (303) 460-1149
 Email: esn@mountainsharetransfer.com
 Address: 2030 Powers Ferry Road SE, Suite # 212, Atlanta, Ga. 30339

Is the Transfer Agent registered under the Exchange Act?³ Yes: X No:

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

Shares Outstanding as of the Second Most Recent Fiscal Year End: **Opening Balance.**

As of 12/31/2020, the number of shares outstanding of our Common Stock was:

1,008,901,842.

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted
03/17/2021	New Issuance	115000000	Common	0.001	Yes	BIG Hollow Family LLC	Services Provided	Restricted
04/06/2021	New issuance	4,000,000	Common	0.001	Yes	BRUCE I. BOND	Services Provided	Restricted
04/06/2021	New issuance	10,000,000	Common	0.001	Yes	BRENTON V. GOULDING	Services Provided	Restricted
04/06/2021	New issuance	10,000,000	Common	0.001	Yes	BLANE R. GOULDING	Services Provided	Restricted
04/06/2021	New issuance	10,000,000	Common	0.001	Yes	PATRICIA J. GOULDING	Services Provided	Restricted
04/06/2021	New issuance	10,000,000	Common	0.001	Yes	BRYCE E. GOULDING	Services Provided	Restricted
04/07/2021	New issuance	25,000,000	Common	0.002	Yes	FREDERICK J BERGER	Purchase	Restricted
07/06/2021	New issuance	5,000,000	Common	0.001	Yes	DANIELLE T. MOROSCO	Services Provided	Restricted

07/30/2021	New issuance	25,000,000	Common	0.001	Yes	MICHAEL M. BERKOWITZ	Services Provided	Restricted
08/13/2021	New issuance	4,000,000	Common	0.001	Yes	STEPHEN M. SWINSON	Services Provided	Restricted
07/29/2021	New issuance	5,000,000	Common	0.001	Yes	JAMES D. WACHENDORFER	Services Provided	Restricted
08/13/2021	New issuance	7,000,000	Common	0.001	Yes	JESSICA VERVILLE	Services Provided	Restricted

Shares Outstanding as of the date of this report.

Shares Outstanding as of March 31, 2022 Common 1,238,901,842, Preferred 10,000,000

The Company had no changes is to the terms of any of its classes outstanding shares from January 1, 2019 through the current date.

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: None

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
- IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

Name: JD Patterson
 Title: Certified Public Accountant
 Relationship to Issuer: Outside Accountant

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance Sheet;
- D. Statement of Income;
- E. Statement of Cash Flows;
- F. Statement of Changes in Shareholders' Equity;
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

Financial Statements: If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

The Annual Financial Statements dated 03/31/22 are incorporated by reference as they are posted on www.otcm Markets.com

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Company's focus is on developing businesses and products in multiple health-related industries including, but not limited to nutraceuticals, cannabinoids and stem cells, with the purpose of creating viable alternatives to toxic pharmaceuticals.

- B. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of such entity's business, contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

Reference is made to the company's website and to OTCMarkets' website for this information.

The Company has shared financial interests with Rushnet, Inc. (trading symbol: RSHN) including, but not limited to shared equity in multiple joint ventures, government grant initiatives, innovative products and more. The Company's focus is on developing and acquiring businesses and products for health-related industries as alternatives to toxic pharmaceuticals. In that pursuit, the Company has been creating new and innovative products, cultivating

distribution arrangements and manufacturing resources. In addition, the Company has acquired and intends to build schools with a focus on Autism. Able Academics will be a focus of new schools and nutraceutical and stem cell alternatives for these afflicted individuals.

Additionally, the company has entered into joint venture relationships with Able Academics Schools and Stemspa.

Additionally, for its products, it has formulated several outstanding distribution networks to include alternatives for physicians to offer our products to their patients as alternative to prescription and often toxic drugs.

Principal Products

The Company's principal products have been formulated and produced. Our initial products focus on specific illnesses common to the mass market. Rare cannabinoids have been harnessed and used in sufficient quantity and in appropriate combinations to render efficacy: Relief Raspberry gummies, Calming Mango and Sleepy Watermelon have key formulations with an obvious purpose suggested in the name. These formulations are unique to the market and have been internally tested for efficacy. Furthermore, their safety is such that multiple gummies can be consumed without issues. These products were designed to work with our nutraceuticals, which alternatively have no CBD in their formulations. These nutraceutical compounds are produced after extensive Research and Development: Inflammplex, EnergyPlex, and Painplex have amazing preliminary results in our internal anecdotal testing and work in conjunction with our gummies to relieve the issues internally.

StemSpa was our latest acquisition. We have specific algorithms for appropriation and administration that we are delivering currently and will be presenting to the mass market shortly. We will be focusing on brick-and-mortar clinics, rendering stem cells to the lay physician and possibly developing off-shore locations for the administration of these mostly umbilical-based products.

Distribution and Marketing

We have developed multiple channels of marketing and are not limiting our efforts to the United States alone, but have eyes on Mexico, Canada and South America as well as the surrounding Island nations. Our marketing will channel physicians, internet and retail facilities. We have teamed up with Virexit to initiate a novel internet marketing campaign that will essentially be a word-of-mouth campaign in digital format. We are currently working on more avenues of distribution and celebrity endorsements.

New Products - The specific products will not be named until they have been trademarked. Fortunately, we now have a facility for their creation. Eden Labs has been astounding in the attention to detail for the first formulations. They were charged with ethanol extraction of the proper portion of appropriate herbs in order to harness the most effective chemicals. This, in turn was reduced to powder after concentrating and placed into capsules. These formulations are expensive, but effective because of the chemistry behind them and the years of clinical knowledge that went into the creation. Our future formulations will be addressing: autism, memory, aging, chronic sleep issues, libido and more. With anticipated funding, we look forward to completing the research and development of these products and mass produce them by the end of 2022.

Competitive Business Conditions

While our formulations cannot truly be protected, we have distinct advantages to the market from being the first out with our targeted products. Our nutraceuticals are being produced after over 20 companies were vetted and only one was able to produce them. Eden is under a non-disclosure agreement for our products.

Unlike other nutraceuticals on the market, ours are formulated to have an instant effect without side-effects. Our Energyplex, for example, gives a noticeable burst of energy and focus without caffeine or sugar.

Our Painplex formulation, works on other pathways than our Raspberry Relief gummy, so that the overall effect is very competitive to the opioid market for relief of discomfort.

Based on its corporate activities, the Company is not a "Shell" nor has ever been characterized as a "Shell" by any governmental agency.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

The address of the issuer's principal place of business is 4 Office Park Drive, Pod 3, Suite L Palm Coast, FL 32137.

7) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, regardless of the number of shares they own. **If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Richard E Goulding, MD</u>	<u>Chairman of the Board</u>	Palm Coast Florida	<u>9,718,000</u>	<u>Series A Preferred Stock</u>	<u>97%</u>	<u>This represents approximately 89% voting control</u>
_____	_____	_____	_____	_____	_____	_____

8) Legal/Disciplinary History

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

The company sued Western Sierra Resource Corp., a publicly traded entity. After a year of litigation, recently, Western Sierra filed a counter suit against Gold River. Our counsel feels that their claim is utterly without merit.

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name:	Gary L. Blum, Esq.
Firm:	Law Offices of Gary L. Blum
Address 1:	3278 Wilshire Boulevard, Suite 603
Address 2:	Los Angeles, California 90010
Phone:	(213) 381-7450
Email:	gblum@gblumlaw.com

Accountant or Auditor

Name: John D. "J.D." Patterson, CPA
Firm: Patterson CPAs, LLC
Address 1: 722 West Shepard Lane, STE 101
Address 2: Farmington, UT 84025
Phone: 801-451-8886
Email: john@gapcpas.com

Investor Relations

Name:
Firm:
Address 1:
Address 2:
Phone:
Email:

Other Service Providers

Provide the name of any other service provider(s) that **assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

10) Issuer Certification*Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, /s/Richard Goulding certify that:

1. I have reviewed this Quarterly Disclosure Statement of Gold River Productions, Inc.; For the Three Month's Ended March 31, 2022.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 15, 2022

[CEO /s/Richard Goulding [Chairman of the Board Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Richard Goulding certify that:

1. I have reviewed this Quarterly financial statement of Gold River Productions, Inc.; For the Three Month's Ended March 31, 2022.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 15, 2022

CFO /s/ Richard Goulding

(Digital Signatures should appear as "/s/ [OFFICER NAME]")